Sign in
Taking people in South KoreaPhase 1/2

Tests AZD3632 alone or with other drugs in advanced blood cancers

Tests the oral drug AZD3632 in adults with advanced leukemia or myelodysplastic syndromes.

Key facts

Who runs it
AstraZeneca
Where
Seoul, South KoreaSee the siteAlso in 8 other countries, 26 sites
Registry title
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Status
Recruiting
Phase
Phase 1/2
People taking part
85 people, planned
Started
9 Jan 2026
Expected to end
15 Feb 2029
Type of study
Interventional, 7 groups
Treatments tested
  • AZD3632
  • Posaconazole
Record updated
23 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 16 and older with advanced acute leukaemia or higher-risk myelodysplastic syndrome that has come back or not responded to treatment, and whose disease has a gene change linked to HOX overexpression.

Age
16 years and older
Sex
All sexes can join.
Disease stage
Advanced acute leukaemia or myelodysplastic syndrome (MDS) that has relapsed or not responded to standard treatment, with measurable disease and no approved treatment left. White blood cell count below 25,000/μL.
Earlier treatment
Must have already had standard treatment, for example 2 cycles of intensive chemotherapy, a hypomethylating agent (HMA) alone, or HMA combinations such as HMA/venetoclax. For MDS, at least 2 cycles of HMA, unless HMA is not possible and no other standard options exist. Recent radiation or other anticancer drugs are not allowed.
Biomarker or test result
A gene change linked to HOX overexpression found by local testing. Backfill participants in Module 1 need KMT2Ar or NPM1m.

Main reasons for not taking part

  • Burkitt lymphoma/leukaemia or acute promyelocytic leukaemia
  • Active leukaemia in the testicles or central nervous system
  • Unresolved side effects of Grade 2 or higher from earlier treatment
  • Abnormal potassium or magnesium levels before the first dose
  • Recent radiation therapy or other anticancer treatment

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Core criteria:
  • Adequate organ function
  • Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies; Module 1:
  • Advanced haematologic malignancy - a) for dose escalation - diagnosis of acute leukemia or myelodysplastic neoplasia (MDS) and harbouring one of the genetic alterations per local testing associated with upregulation of HOX; b) for Backfill - diagnosis of harbouring a KMT2Ar or NPM1m per local testing
  • Participants must have measurable disease that is relapsed/refractory to conventional therapies known to be effective for their disease and not have any available approved therapies.: a) Relapsed and primary refractory acute leukaemia after standard of care therapy including but not limited to 2 cycles of intensive chemotherapy, hypomethylating agent (HMA) monotherapy, or HMA combinations such as HMA/venetoclax.; b) Relapsed and primary refractory MDS is defined by ≥ 5% blasts in the bone marrow and/or persistence of peripheral blasts after treatment with at least 2 cycles of HMA. Participants ineligible for the treatment with an HMA and without any other standard of care (SoC) options are allowed to enrol; c) White blood cell count below 25,000/μL. Participants may receive cytoreduction per protocol-specified criteria; d) Performance status: Eastern Cooperative Operative Group (ECOG) ≤ 2; e) Life expectancy: ≥ 8 weeks; Module 2:
  • Participants must have measurable disease that is relapsed/refractory to conventional therapies known to be effective for their disease and not have any available approved therapies.: a) Relapsed and primary refractory acute leukaemia after standard of care therapy including but not limited to 2 cycles of intensive chemotherapy, HMA monotherapy, or HMA combinations such as HMA/venetoclax.; b) Relapsed and primary refractory MDS is defined by ≥ 5% blasts in the bone marrow and/or persistence of peripheral blasts after treatment with at least 2 cycles of HMA. Participants ineligible for the treatment with an HMA and without any other SoC options are allowed to enrol; c) White blood cell count below 25,000/μL. Participants may receive cytoreduction per protocol-specified criteria; d) Performance status: ECOG ≤ 2; e) Life expectancy: ≥ 8 weeks

Who cannot take part

  • Unresolved treatment-related toxicities Grade ≥ 2 from prior therapy
  • Receipt of non-CNS radiation therapy within 2 weeks and of CNS radiation within 8 weeks of the first scheduled dose
  • Receipt of any investigational or non-investigational anticancer agents, including non-biologic agents, biologic agents and/or prior treatment other menin inhibitors (backfill participants only)
  • Receipt of any non-investigational anticancer agents, including non-biologic agents and/or biologic agents or receipt of non-CNS or CNS radiation therapy
  • Participants for whom treatment with posaconazole is contraindicated per the local prescribing information
  • For nested food effect participants - diagnosis of diabetes mellitus (Type I or Type II); Module 2:
  • Abnormal levels of potassium or magnesium prior to first dose of AZD3632; Module 1:
  • Core criteria:
  • Participants with Burkitt lymphoma/leukaemia or Acute Promyelocytic Leukaemia
  • Active testicular or active central nervous system (CNS) (> CNS1 or radiographic) involvement by leukaemia

Where in South Korea

Also in 8 other countries, 26 sites

  • SeoulHospital not named in the registryTaking people

About the trial

What the trial wants to find out

The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.

The 7 groups in the trial

  • Module 1: AZD3632 dose 1Treatment being tested

    Participants will receive AZD3632 (dose 1) through the treatment period.

    Treatment: AZD3632

  • Module 1: AZD3632 dose 2Treatment being tested

    Participants will receive AZD3632 (dose 2) through the treatment period.

    Treatment: AZD3632

  • Module 1: AZD3632 dose 3Treatment being tested

    Participants will receive AZD3632 (dose 3) through the treatment period.

    Treatment: AZD3632

  • Module 1: AZD3632 dose 4Treatment being tested

    Participants will receive AZD3632 (dose 4) through the treatment period.

    Treatment: AZD3632

  • Module 1: AZD3632 dose 5Treatment being tested

    Participants will receive AZD3632 (dose 5) through the treatment period.

    Treatment: AZD3632

  • Module 1: AZD3632 dose 6Treatment being tested

    Participants will receive AZD3632 (dose 6) through the treatment period.

    Treatment: AZD3632

  • Module 2: AZD3632 + posaconazoleTreatment being tested

    Participants will receive AZD3632 alone, then will receive AZD3632 in combination with posaconazole through treatment period.

    Treatment: AZD3632 and Posaconazole

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Plain-language title
Tests AZD3632 alone or with other drugs in advanced blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
23 October 2026